2
Clinical Trials associated with Alhydrogel adjuvanted Pfs230D1M-EPA(National Institute of Allergy & Infectious Diseases)Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali
Background:
Researchers are looking for new ways to control and eradicate malaria. They want to test vaccines to block malaria transmission in adults in Mali. These vaccines work by inducing antibodies in a person. The antibody is then taken up with blood by a mosquito that bites the person. This blocks parasite development in the mosquito. This stops malaria transmission to another person.
Objective:
To test the safety, reactogenicity, immunogenicity, and transmission-blocking activity of the vaccines Pfs25M-EPA and Pfs230D1M-EPA with AS01 in Malian adults.
Eligibility:
Healthy Malians ages 18-50 living in certain areas in Mali who:
Are not pregnant or breastfeeding
Are not infected with HIV, Hepatitis B and Hepatitis C
Do not have evidence of immunodeficiency
Do not have history of severe allergic reaction or anaphylaxis
Design:
Participants will be screened with:
Medical history
Physical exam
Malaria Comprehension Exam
Blood and urine tests
Electrocardiogram (for participants in certain study groups)
Participants will be randomly assigned to a study group.
Participants will be monitored for 12-16 months. For the first 7 months, they will have between 1 and nine visits a month. The number depends on the month and on what group they are in. For the rest of the months, they will have 1 monthly visit.
Each visit includes a physical exam. Most include blood tests.
Participants will get 3 doses of a study or comparator vaccine. They get the vaccine through an injection in the upper arm. This occurs at their first visit, then 1 month later, and then 5 months later.
Participants will be followed for at least 6 months after the last vaccine.
If participants develop an injection site rash or reaction, photographs may be taken of the site.
Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali
Background:
- Malaria is a severe infection caused by a parasite. People can get malaria if a mosquito that carries the parasite bites them. Malaria infection does not happen in the United States, but many people in Africa, Asia, and South America are at risk for it. Researchers want to test two vaccines that may help decrease malaria infection.
Objective:
- To see if two vaccines (Pfs25M-EPA/Alhydrogel and Pfs230DIM-EPA/Alhydrogel ) are safe in humans and cause an immune response that will prevent malaria parasites from correctly growing in the mosquito.
Eligibility:
- Healthy adults ages 18 50.
Design:
There are several groups in this study. Each group will receive a different dose of the vaccine and some groups will received both vaccines.
Vaccinations will be given on two days about 4 weeks apart.
Participants will receive each vaccine as an injection into the arm. Blood will be drawn on the day of vaccination.
In the 4 weeks after receiving a vaccination, participants will have at least 3 clinic visits and 1 phone contact. They will have at least 3 more visits and 3 phone contacts over the next 6 months.
At each visit, participants will be evaluated for side effects to the vaccine and any new health changes or problems. They will be asked how they are feeling and if they have taken any medicine. Blood and urine samples may be taken at the visit. More follow-up visits may be needed to follow up on changes or problems.
100 Clinical Results associated with Alhydrogel adjuvanted Pfs230D1M-EPA(National Institute of Allergy & Infectious Diseases)
100 Translational Medicine associated with Alhydrogel adjuvanted Pfs230D1M-EPA(National Institute of Allergy & Infectious Diseases)
100 Patents (Medical) associated with Alhydrogel adjuvanted Pfs230D1M-EPA(National Institute of Allergy & Infectious Diseases)
100 Deals associated with Alhydrogel adjuvanted Pfs230D1M-EPA(National Institute of Allergy & Infectious Diseases)